SELB
- Selecta Biosciences, Inc.
()
Overview
Company Summary
Selecta Biosciences, Inc. (SELB) is a biotechnology company that specializes in the development of targeted immunotherapies and drugs for various diseases. The company combines its proprietary Synthetic Vaccine Particle (SVP) platform with antigen-specific immunotherapies to design and produce therapies for patients in need.
Selecta's Synthetic Vaccine Particle technology allows for the precise engineering and modification of nanoparticles, enabling the development of therapies that can trigger an immune response in a specific and controlled manner. This platform has broad applications across different diseases by enabling the targeting and modulation of immune cells.
One of Selecta's key focus areas is the treatment of rare and serious diseases caused by undesired immune responses in the body. The company develops therapies to address conditions such as enzyme deficiencies, autoimmune diseases, and allergies. Through its platform technology, Selecta aims to deliver targeted therapies that can potentially lessen or eliminate the negative effects of the immune response while preserving important immune functions.
Selecta Biosciences collaborates with pharmaceutical and biotechnology partners to advance the development and commercialization of its product candidates. The company's ultimate goal is to provide innovative and effective treatments for patients suffering from a range of diseases, leveraging their expertise in immunotherapy and building on the potential of the Synthetic Vaccine Particle platform.